multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacyand safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferativeglomerulonephritis (IC-MPGN).

Project: Research project

Project Details

Description

multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN).
StatusActive
Effective start/end date7/11/23 → 8/19/28

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint